Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple solid tumors
- New trial
Multiple solid tumors
Phase 1 Trial of XB371 Topoisomerase Inhibitor
This trial evaluates first-in-human TF–topoisomerase-I inhibitor ADC (XB371), in participants with locally advanced or metastatic solid tumors. Using dose-escalation cohorts and randomized expansion parts A and B,…
NCT07123103 First-in-human - New trial
Multiple solid tumors
Phase 1a/b study of LY4257496, a GRPR-targeted beta emitter radioligand
This two-part, open-label trial evaluates safety, tolerability, and preliminary efficacy of LY4257496 administered alone or with standard-of-care agents—including fulvestrant, imlunestrant, aromatase inhibitor,…
NCT07114601 First-in-human - New trial Spotlight
Multiple solid tumors
Phase I/II Trial of AZD6750, CD8-guided IL-2 fusion protein, in advanced solid tumors
This trial evaluates the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD6750 as a single agent or in combination with rilvegostomig—a Tigit and PD-1 bispecific mAb—in adult participants…
NCT07115043 First-in-human - New trial
Multiple solid tumors
Phase Ia/b study of DSB2455, a PARP1 inhibitor in advanced malignancies
This Phase Ia/b open-label adaptive trial evaluates the safety, tolerability, and activity of DSB2455, a small molecule PARP1 selective inhibitor, as monotherapy in participants with advanced or metastatic breast,…
NCT06458712 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 ALX2004 Antibody-Drug Conjugate Targeting EGFR in Advanced Solid Tumors
This phase 1 study evaluates ALX2004, an antibody drug conjugate targeting EGFR, in an open-label, multicenter trial featuring dose escalation, exploration, and expansion phases to determine the recommended phase 2…
NCT07085091 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 trial of ERAS-4001, a pan-KRAS-targeted agent
This first-in-human open-label study evaluates the safety, tolerability, and preliminary efficacy of ERAS-4001 given orally as monotherapy and in combination with another investigational drug in a dose optimization…
NCT07021898 First-in-human - New trial
Multiple solid tumors
Phase 1 study of MK-4700 (investigational immune modulator) with PD-1 inhibitor pembrolizumab (mechanism undisclosed)
Merck Sharp & Dohme is sponsoring this open-label trial to evaluate escalating doses of MK-4700 as monotherapy and in combination with pembrolizumab in patients with advanced or metastatic solid tumors including…
NCT06894771 First-in-human - New trial
Multiple solid tumors
Phase 1 study of KQB168, an investigational anti-tumor agent, with pembrolizumab PD-1 inhibitor (mechanism undisclosed)
This open-label, multicenter dose escalation trial by Kumquat Biosciences Inc. evaluates oral KQB168 alone or with intravenous pembrolizumab to determine safe dosing and early efficacy in adults with advanced,…
NCT06994806 First-in-human - New trial
Multiple solid tumors
Phase 1 MOMA-341 study: Novel DNA damage response modulator in advanced solid tumors
This multi-center Phase 1 trial by MOMA Therapeutics evaluates the safety, tolerability, pharmacokinetics, and preliminary clinical activity of MOMA-341, a WRN helicase inhibitor, given as monotherapy or in…
NCT06974110 First-in-human - New trial
Multiple solid tumors
Pilot Phase RFA/BA+RT for metastatic spine lesions: Radiofrequency ablation & radiotherapy
This pilot randomized controlled study evaluates RFA with bone augmentation plus radiotherapy versus radiotherapy alone in patients with metastatic spine lesions from solid tumors (T5-L5). RFA employs…
NCT07090122 Exploratory - New trial
Multiple solid tumors
Phase I trial of HS-20110, a novel antibody drug conjugate for advanced solid tumors
This open-label, multicenter Phase I trial evaluates HS-20110’s safety, tolerability, pharmacokinetics and initial efficacy in patients with advanced solid malignant tumors. The study includes a dose escalation…
NCT06892379 First-in-human - Trial result Spotlight
Multiple solid tumors
BHV‑1510 Trop2‑TopoIx ADC Shrinks Tumors in 6/6 Patients; FGFR3 ADC BHV‑1530 Enters Clinic
BHV‑1510 is a Trop2‑targeted antibody—drug conjugate armed with Biohaven’s proprietary TopoIx topoisomerase I payload; in the first Phase 1 cohorts (monotherapy and in combo with the anti‑PD‑1 antibody cemiplimab)…
- New trial
Multiple solid tumors
Phase 1/2 MK-3120 trial of a selective receptor tyrosine kinase inhibitor.
This Phase 1/2, open-label trial conducted by Merck Sharp & Dohme LLC investigates the safety, dosing, and initial efficacy of MK-3120, a selective receptor tyrosine kinase inhibitor, in participants with advanced,…
NCT06818643 First-in-human - New trial
Multiple solid tumors
Phase 1 ABSK-011, a novel kinase inhibitor, in advanced solid tumors.
This open-label phase 1 trial enrolls patients with hepatocellular carcinoma and other advanced solid tumors who are intolerant of or have failed standard therapies. During the dose-escalation phase, participants…
NCT04906434 First-in-human - New trial
Multiple solid tumors
Phase I study of RO7673396, a RAS pathway inhibitor in advanced tumors
This study evaluates the safety and preliminary anti-tumor activity of RO7673396 in patients with advanced solid tumors harboring RAS mutations. In Stage 1, patients receive escalating doses to determine the…
NCT06884618 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2a trial of NTS071, a TP53 Y220C directed activator
This Phase 1/2a study by Nutshell Therapeutics (Shanghai) Co., LTD. evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in adults with advanced solid tumors harboring a TP53 Y220C…
NCT07060989 First-in-human - New trial
Multiple solid tumors
Phase 1/2 AVZO-1418 trial of investigational tyrosine kinase inhibitor
This Phase 1/2 study evaluates safety, tolerability, pharmacokinetics, and antitumor activity of AVZO-1418, an investigational tyrosine kinase inhibitor, administered intravenously as a monotherapy and in combination…
NCT07038343 First-in-human - New trial
Multiple solid tumors
Phase 1 [18F]CSB-321: Radiolabeled PET imaging agent for mapping immunotherapy response.
This open-label, non-randomized multi-cohort study evaluates up to three doses of [18F]CSB-321—a novel radiolabeled PET imaging agent—in participants with metastatic or unresectable solid tumors, including melanoma,…
NCT07057349 First-in-human - New trial
Multiple solid tumors
Phase 1 Pilot: 111In-ABD147 DLL3-Targeting Imaging Agent for Metastatic Cancer
This pilot trial by Thomas Hope evaluates the safety and imaging performance of 111In-ABD147—a DLL3-targeting agent radiolabeled for SPECT—in patients with metastatic solid tumors, castration-resistant prostate…
NCT07052760 First-in-human - New trial
Multiple solid tumors
Phase 3 Trial: Radiation Therapy (DNA-damaging agent) for High-Risk Bone Metastases
This study evaluates if adding radiation therapy—which uses high energy x-rays to damage cancer cell DNA—to standard care reduces complications in solid tumor patients with asymptomatic high-risk bone metastases.…
NCT06745024 Registrational - New trial Spotlight
Multiple solid tumors
Phase 1 trial of MGC028, an ADAM9-directed Topo I inhibitor ADC for advanced solid tumors.
This Phase 1 study led by MacroGenics evaluates safety, tolerability, and optimal dosing of MGC028 in adult patients with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors.…
NCT06723236 First-in-human - New trial Spotlight
Multiple solid tumors
Phase II ADC MATCH: sacituzumab govitecan (Trop‑2 ADC), enfortumab vedotin (nectin‑4 ADC), trastuzumab deruxtecan (HER2 ADC) trial
This Phase II study by the National Cancer Institute uses molecular screening with IHC assays to assign patients with advanced solid tumors lacking standard care options to one of three treatment cohorts. In each…
NCT06311214 Exploratory - New trial
Multiple solid tumors
Phase 1 SBO-154 trial of novel MUC1 ADC
This Phase 1 multicenter open-label study evaluates SBO-154, an investigational MUC1 antibody drug conjugate (ADC) for safety, tolerability, and preliminary efficacy in patients with advanced, relapsed, and…
NCT07042100 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 study of ERAS-0015, a RAS inhibitor small molecule.
This open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of ERAS-0015 administered alone or with additional investigational agents in patients with advanced or metastatic…
NCT06983743 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 TNG462 PRMT5 inhibitor trial with KRAS inhibitor combinations.
This open-label, multicenter trial evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral TNG462 combined with investigational KRAS agents RMC-6236 or RMC-9805…
NCT06922591 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 trial ARV-806 KRAS (G12D) inhibitor in advanced cancer.
This open-label Phase 1/2 study evaluates ARV-806 administered via IV infusion in adults with advanced KRAS G12D-mutated tumors, including metastatic pancreatic ductal adenocarcinoma. Sponsored by Arvinas Inc. and…
NCT07023731 First-in-human - New trial
Multiple solid tumors
Phase 1/2 Patritumab Deruxtecan, HER3-directed Topoisomerase I Inhibitor ADC
The study evaluates safety, PK, and efficacy of patritumab deruxtecan as monotherapy in children with relapsed or refractory hepatoblastoma or rhabdomyosarcoma, given via IV every 3 weeks. The trial, conducted by…
NCT06941272 Exploratory - New trial
Multiple solid tumors
Phase I/II trial: DT2216, a BCL‑xL degrader, combined with irinotecan for refractory pediatric cancers
This phase I/II trial by the Children’s Oncology Group evaluates the safety, tolerability, and preliminary efficacy of DT2216 with irinotecan in children, adolescents, and young adults with relapsed or refractory…
NCT06620302 Exploratory - New trial
Multiple solid tumors
Phase 1b/2 Evorpacept trial: CD47-binding Ig Fc fusion protein in oncology.
This study evaluates evorpacept in combination with anti-cancer therapies in advanced and metastatic tumors. The trial enrolls patients with HER2+ breast, colorectal, and head and neck cancers in both randomized and…
NCT07007559 Exploratory - New trial
Multiple solid tumors
Phase 1 AB821 trial of CD8-targeted IL-21 immunotherapy.
This open-label, dose-escalation study at Yale University in New Haven evaluates AB821 monotherapy given every 2 weeks in adults with recurrent, locally advanced or metastatic melanoma and other immune-responsive…
NCT07027488 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.